Market Analysis & Segmentation

Bioshares Biotech Summit July 2016

Duncan Ross Managing Director & CEO

1

Disclaimer

This presentation has been prepared by AtCor Medical Holdings Limited (AtCor or the Company) solely for its use at presentations to be made by the Company. The information contained in this presentation is an overview and does not contain all information necessary to make investment decisions. Although reasonable care has been taken to ensure that facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation and no reliance should be placed on such information or opinions. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial advice nor take into consideration your investment objectives.

This presentation contains or may contain forward‐looking statements that are based on management's belief, assumptions and expectations and on information currently available to management. All statements that are not historical, including those statements that address future operating performance and events of developments that we expect or anticipate will occur in the future, are forward looking statements. Although management believes these forward looking statements are fair and reasonable you should not place undue reliance on these statements.

Session Topic: Market Analysis & Segmentation

The links between product market research and competitor analysis will be explored in this session.

Great partnering deals can only be as good as the products they are based on, and those products must be optimised to fit in a competitive market place.

  • Where do the commercial opportunities exist and why?

  • How do market opportunities and changing market needs drive business and business development opportunities?

    This presentation will focus on:

  • The changing market dynamics that affect AtCor's business

  • How AtCor is addressing these changing business opportunities

  • The company's competitive position

  • Where to direct investment to capitalise on the expanding environment for AtCor products

Game Changing Technology Delivered on 3 Distinct Platforms

SphygmoCor is the global gold standard for noninvasively measuring central aortic pulse waveforms to determine central aortic pulse pressure, augmentation index, reflected wave magnitude (a key measure of arterial stiffness) and pulse wave velocity.

SphygmoCor EM series

Primary focus is research and clinical specialist market. Provides central pressures, pulse wave velocity & heart rate variability.

Cleared for sale in all major markets, including USA (FDA), Europe (CE Mark), Australia (TGA), Canada, Japan, China, Brazil.

SphygmoCor XCEL series

Main markets are clinical practice and pharmaceutical trials. Provides brachial

blood pressure, central pressures and pulse wave velocity.

Cleared for sale in most major markets, including USA (FDA), Europe (CE Mark), Australia (TGA), Canada, Mexico, China.

Oscar 2 with SphygmoCor Inside

24 hour ambulatory blood pressure monitor with central pressures. Largest market is pharmaceutical trials followed by clinical practice and research.

Cleared for sale in USA (FDA), Europe (CE Mark), Australia (TGA).

AtCor Medical Holdings Limited published this content on 29 July 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 29 July 2016 00:16:10 UTC.

Original documenthttp://atcormedical.com/wp-content/uploads/2016/07/ACG0377.pdf

Public permalinkhttp://www.publicnow.com/view/2E93D6CD5216B699948ED03FDC6A11E51F1CFB83